Related Experiment Video

Updated: Feb 4, 2026

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.4K

Nimotuzumab: beyond the EGFR signaling cascade inhibition

Zaima Mazorra1, Lisset Chao2, Anabel Lavastida1

  • 1Clinical Direction, Center of Molecular Immunology, Havana, Cuba.

Seminars in Oncology
|October 16, 2018
PubMed

Insights

Nimotuzumab, an antibody targeting epidermal growth factor receptor (EGFR), shows promise in cancer immunotherapy by activating T-cells. This review highlights its unique properties and immune-response-activating capacity for potential vaccine-like effects.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Epidermal growth factor receptor (EGFR) family members are key oncogenes driving carcinogenesis and immune evasion.
  • Targeting EGFR is a validated strategy in cancer immunotherapy.
  • Some EGFR-targeting agents exhibit vaccine-like effects by activating T-cells.

Purpose of the Study:

  • To review the properties of nimotuzumab, an EGFR-specific monoclonal antibody.
  • To compare nimotuzumab with other EGFR-targeting monoclonal antibodies.
  • To highlight nimotuzumab's immune-activating capacity and clinical effects.

Main Methods:

  • Review of existing literature on nimotuzumab and EGFR-targeting therapies.
  • Pharmacodynamic and clinical data analysis.
  • Comparison of nimotuzumab's mechanisms of action with other agents.

Main Results:

  • Nimotuzumab is an IgG1 humanized monoclonal antibody targeting the extracellular domain of EGFR.
  • It exhibits unique pharmacodynamic properties allowing long-term, low-toxicity treatment.
  • Emerging evidence suggests nimotuzumab activates innate and adaptive immune responses.

Conclusions:

  • Nimotuzumab demonstrates potential beyond simple EGFR signaling inhibition.
  • Its capacity to activate immune responses distinguishes it from other EGFR antibodies.
  • Further clinical trials are investigating biomarkers for nimotuzumab efficacy.
Keywords:
EGFRHLA class I moleculesT cellsantibody-dependent cell mediated cytotoxicity (ADCC)monoclonal antibodiesnatural killer cells

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.6K
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

9.3K

Related Concept Videos

Intracellular Signaling Cascades01:24

Intracellular Signaling Cascades

Once a ligand binds to a receptor, the signal is transmitted through the membrane and into the cytoplasm. The continuation of a signal in this manner is called signal transduction. Signal transduction only occurs with cell-surface receptors, which cannot interact with most components of the cell, such as DNA. Only internal receptors can interact directly with DNA in the nucleus to initiate protein synthesis. When a ligand binds to its receptor, conformational changes occur that affect the...
53.6K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
8.4K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
18.5K
Rab Cascades01:25

Rab Cascades

Rab GTPases act in a regulated cascade during membrane fusion, helping the lipid bilayers mix. The Rab family of proteins are active when bound to GTP, and inactive when bound to GDP. Hence, they act as guanine nucleotide-dependent molecular switches. Rab-GTP recognizes and binds to long or short-range tethering proteins to capture the target vesicle. These tethers coordinate with SNAREs on the vesicle and the target membrane to assemble the trans SNARE complex that locks the mixing bilayers.
3.6K
Feedback Inhibition00:46

Feedback Inhibition

Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
57.1K
Yeast Signaling01:28

Yeast Signaling

Yeasts are single-celled organisms, but unlike bacteria, they are eukaryotes (cells with a nucleus). Cell signaling in yeast is similar to signaling in other eukaryotic cells. A ligand, such as a protein or a small molecule released from a yeast cell, attaches to a receptor on the cell surface. The binding stimulates second-messenger kinases to activate or inactivate transcription factors that further regulate gene expression. Many of the yeast intracellular signaling cascades have similar...
17.3K